Articles tagged with: Actimid
News»

Pomalidomide has demonstrated efficacy in heavily pre-treated multiple myeloma patients who have been treated with – or are even refractory to – Revlimid and Velcade.
Three studies of the use of pomalidomide (Pomalyst) in relapsed and refractory multiple myeloma patients were presented yesterday at the American Society of Hematology annual meeting in Orlando.
Pomalidomide, which is being developed by the pharmaceutical company Celgene, is an immunomodulatory agent that induces the immune system to destroy myeloma cells. It belongs to the same class of drugs as Revlimid (lenalidomide) and thalidomide (Thalomid). …
News»

The year 2009 brought a lot of new and exciting advancements in the field of multiple myeloma. Over the course of 2009, The Myeloma Beacon covered more than 100 important myeloma-related studies.
To highlight the most important of these studies, the Myeloma Beacon surveyed leading physicians and researchers in the field. These physicians and researchers were asked to name the three peer reviewed journal articles published in 2009 and the three conference abstracts from 2009 that have the most important findings or implications relating to multiple myeloma.
The top three journal …
News, Resources»

Dr. Robert Kyle, a leading myeloma physician, researcher, and professor at the Mayo Clinic, spoke with The Myeloma Beacon about his approach to treating multiple myeloma patients; participation in clinical trials; many of the key issues for myeloma patients and physicians, including conventional and alternative treatment options; and the future of personalized medicine.
This article is the second part of a two-part series based on the Beacon’s conversations with Dr. Kyle. It will cover the role of clinical trials and key issues in the treatment of multiple myeloma as well as promising …
News»

At the upcoming meeting of the American Society of Hematology (ASH), there will be several presentations about Actimid (pomalidomide). Actimid, a new drug being developed by Celgene Corporation as a treatment for multiple myeloma, is a molecular derivative of thalidomide (Thalomid).
Actimid As A Combination Therapy With Dexamethasone
One of the ASH presentations will show that the combination regimen of Actimid and low-dose dexamethasone (Decadron) is an effective treatment for relapsed multiple myeloma.
Actimid was tested in combination with dexamethasone in 34 patients with relapsed myeloma following therapy with
News»

Researchers at St George’s, University of London have developed a new directory that could lead to quicker and more targeted treatment for multiple myeloma and other cancer patients.
The directory identifies 40,000 genes that can cause cancer and lists the effects on each gene by three drugs used in the treatment of multiple myeloma.
The three drugs included in the directory are thalidomide (Thalomid), Revlimid (lenalidomide), and Actimid (pomalidomide, CC-4047). Both thalidomide and Revlimid are approved for the treatment of multiple myeloma. Actimid is still being tested for multiple …
News»

The Journal of Clinical Oncology has reported that a combination regimen of Actimid (pomalidomide) and low-dose dexamethasone (Decadron) in a Phase 2 clinical trial was highly effective in the treatment of relapsed and refractory multiple myeloma patients.
Actimid belongs to a class of therapeutic agents called immunomodulatory drugs (IMiDs), which are molecular analogs of thalidomide (Thalomid). Thalidomide acts on myeloma tumors by inhibiting the growth of new blood vessels. In addition to this mechanism, IMiDs prevent the development of abnormal tissue masses called neoplasms and induce programmed cell death. …
News»
A number of new drugs are on the horizon for relapsed and refractory patients, as discussed by physicians at the 2009 International Myeloma Workshop (IMW). The discussion covered drugs in all stages of development, from those still undergoing initial lab testing to ones already in international clinical trials.
Overall responsiveness to treatment has improved dramatically with the recent introduction of more potent agents such as Revlimid (lenalidomide) and Velcade (bortezomib). Doctors are now testing combinations of these two drugs with newer pharmaceuticals. Of the two, Velcade has been …